SEO URLwww.firestrike.ai/deals/epizyme-ipsen-acquisition-2026
acquisitionAnnounced · Mar 9, 2026biotechnologySource · CredibleArticle · Factual
Ipsen acquires Epizyme
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Epizyme
NASDAQ: EPZM · Cambridge, Massachusetts
Acquirer
Ipsen
Full Acquisition
Status
Completed
Ipsen agreed to acquire Epizyme. Reported deal value: Undisclosed. Status: Completed. Sector: biotechnology. Target headquarters context: Cambridge, Massachusetts, United States.
This page summarizes publicly available information about the transaction as of 2026-03-09. Figures and status may change as filings and press coverage update.
Epizyme eventually sold itself to Ipsen in 2022 struck while confirmatory trials of Tazverik were ongoing
Deal timeline
Announced
Mar 9, 2026 · biopharmadive.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology. Figures and status may change as sources update.
Sources: biopharmadive.com · Primary article · FireStrike proprietary index